Перейти к содержанию

BeOne Medicines Ltd. (ONC) stock: revenue, earnings & dividend

BeOne Medicines Ltd. (ONC, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener ONC · Nasdaq Pharma & Biotech CH-

Key figures

Fiscal year
2025
Revenue
5.34 bn $
Revenue growth
40.2 %
Revenue growth 5y (p.a.)
76.9 %
Net income
287 m $
Net margin
5.4 %
Operating margin
8.4 %
Earnings per share (diluted)
0.19 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
8.19 bn $
Equity
4.36 bn $
Equity ratio
53.3 %
Return on equity
6.6 %
Cash
4.55 bn $
Operating cash flow
1.13 bn $
Free cash flow
942 m $
Shares outstanding
1,484,939,031

History

Revenue by fiscal year

2016 1.07 m $
2017 238 m $
2018 198 m $
2019 428 m $
2020 309 m $
2021 1.18 bn $
2022 1.42 bn $
2023 2.46 bn $
2024 3.81 bn $
2025 5.34 bn $

Net income by fiscal year

2016 -119.22 m $
2017 -93.11 m $
2018 -673.77 m $
2019 -948.63 m $
2020 -1.62 bn $
2021 -1.46 bn $
2022 -2 bn $
2023 -881.71 m $
2024 -644.79 m $
2025 287 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20255.34 bn $287 m $0.19 $–1.13 bn $
20243.81 bn $-644.79 m $-0.47 $–-140.63 m $
20232.46 bn $-881.71 m $-0.65 $–-1.16 bn $
20221.42 bn $-2 bn $-1.49 $–-1.5 bn $
20211.18 bn $-1.46 bn $-1.21 $–-1.3 bn $
2020309 m $-1.62 bn $-1.50 $–-1.28 bn $
2019428 m $-948.63 m $-1.22 $–-750.27 m $
2018198 m $-673.77 m $––-547.72 m $
2017238 m $-93.11 m $––12.8 m $
20161.07 m $-119.22 m $––-89.51 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)